How Post-Approval GMP Challenges Cooled Novo Nordisk’s Blazing Wegovy Launch

Unrelated US FDA inspection led contract manufacturer to stop filling Wegovy syringes before alternate manufacturing facilities became available.

Syringe filling operations
the syringes must be filled before the prescriptions can be filled • Source: Alamy

Novo Nordisk A/S’s US obesity sales force had just gathered in Las Vegas, NV, to prepare for the launch of its Wegovy (semaglutide) weight-loss drug when the company learned on 17 December that it would produce very little new product for at least six months due to manufacturing quality issues.

More from Manufacturing

Will They Or Won’t They? Tariff Questions Loom For Drugmakers

 

Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.

Gene Therapy ‘Survival Of The Fittest’ – Why Companies Need To Understand Health Systems

 

Cell and gene therapy manufacturers must consider the practicalities of their product within the context of a health care system before it comes onto the market to be successful, experts from Novartis, AstraZeneca and England’s National Health Service say.

Global Pilot Reduces Drug Manufacturing Inspections With Hybrid Approach

 
• By 

A global collaborative inspections pilot reduced the number of individual inspections for participating manufacturing facilities, demonstrating that multiple regulatory authorities can carry out joint inspections using a mix of on-site and remote approaches.

UK MHRA Prepares To Roll-Out Decentralized Manufacturing Framework

 
• By 

The UK’s medicines regulator is pressing on with clarifying its expectations on decentralized manufacturing of medicines.

More from Compliance

Global Pilot Reduces Drug Manufacturing Inspections With Hybrid Approach

 
• By 

A global collaborative inspections pilot reduced the number of individual inspections for participating manufacturing facilities, demonstrating that multiple regulatory authorities can carry out joint inspections using a mix of on-site and remote approaches.

UK MHRA Prepares To Roll-Out Decentralized Manufacturing Framework

 
• By 

The UK’s medicines regulator is pressing on with clarifying its expectations on decentralized manufacturing of medicines.

How To Leverage US FDA’s ‘Consistent With Labeling’ Guidance In DTC Ads

 
• By 

Sponsors should review longstanding agency concepts on consumer-friendly language and claims limitations, along with Office of Prescription Drug Promotion research and enforcement, when applying the 2018 CFL guidance to direct-to-consumer advertising, Sidley Austin’s Cope says.